Piramal Pharma falls 5% after FDA lists 3 observations on US facility
Piramal Pharma reassured stakeholders that the observations were classified under the Voluntary Action Indicated (VAI) category and did not involve issues related to data integrity
Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regualtion 30 of the SEBI (Listing Obligations and Disclsoure requirements) Regulations, 2015 - US FDA Inspection at Company''s Riverview Facility. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference Call on the financial results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2023.
Piramal Pharma Q3 Results Review - Gradual Revival In Overall Performance: Motilal Oswal
Outlook remains promising for contract development manufacturing organisation, complex hospital generics segments Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the financial results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2023 Piramal Pharma Ltd - 543635 - Intimation For Change In Website Of The Company
This is to inform you that new website of Piramal Pharma Limited is www.piramalpharmalimited.com Q3FY24 Quarterly & 9MFY24 Result Announced for Piramal Pharma Ltd.
Pharmaceuticals company Piramal Pharma announced Q3FY24 & 9MFY24 results: Revenue from Operations grew by 14% YoY both in Q3FY24 and 9MFY24, driven by double-digit growth across all the three businesses Q3FY24: Rs 1,959 crore (14% YoY growth) 9MFY24: Rs 5,619 crore (14% YoY growth) EBITDA grew by 94% YoY and 71% YoY in Q3FY24 and 9MFY24 respectively, primarily driven by operating leverage, reduction in raw material cost & energy prices, cost optimization, and operational excellence initiatives Q3FY24: Rs 330 crore (94% YoY growth) 9MFY24: Rs 815 crore (71% YoY growth) Net Debt / EBITDA ratio has improved over the last three quarters on account of healthy growth in EBITDA and repayment of debt from the proceeds of the recently concluded Rights Issue Sustainability - Taken a target to reduce Scope 1 and Scope 2 emissions by 42% by FY30 (with a baseline of FY22), which is in accordance with the 1.5 degrees C trajectory suggested by SBTi. Further, we have also taken a target to reduce Scope 3 emissions by 25% by FY30 (with a baseline of FY22) Nandini Piramal, Chairperson, Piramal Pharma said, “We continue to build on our improved performance in FY24 with 14% YoY revenue growth in Q3 along with a significant improvement in EBITDA margin. Our CDMO business is delivering healthy growth with robust order inflows, especially for differentiated offerings and innovation-related work. Our Inhalation Anesthesia portfolio is registering good volume growth in our key market of the US and is also seeing increasing traction in ROW markets. Our India Consumer Healthcare business is delivering steady growth driven by our power brands and contributions from new product launches. On the sustainability front, we have taken significant reduction targets for our Scope 1, 2, and 3 GHG emissions by FY2030. We are also working on multiple initiatives in the areas of water conservation, responsible waste disposal, gender diversity, employee safety, sustainable supply chain, and community development. We look forward to continuing our momentum in Q4 and ending the financial year on a positive note.” Result PDF
Piramal Pharma Shares Hit 52-Week High After Q3 Operating Profit Leaps Threefold
The growth in Ebitda was driven by a decline in raw material and energy prices as well as cost optimisation, according to an exchange filing on Tuesday. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency report for the quarter ended 31st December 2023. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Investor Presentation
Press Release and Investor Presentation of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December 2023.